Healthcare solutions provider Indegene Pvt. Ltd has bought US-based Encima Group in its third acquisition within a year.
The deal will help Indegene strengthen its analytics and omni-channel digital solutions capability for the pharmaceutical industry, the company said in a statement.
A company spokeswoman said the deal is worth $16 million (Rs 109.54 crore).
Encima helps clients in the pharmaceutical and life sciences industries establish enterprise capabilities in marketing and analytics, according to its website.
Life sciences companies are facing challenges in engaging health service providers and patients with the shift to more digital channels, Indegene CEO Manish Gupta said in the statement. The acquisition of Encima will help decode customer behaviour and rationalise brand engagement spends to channels that deliver highest return on investments, he added.
Bangalore-based Indegene has made a string of acquisitions in the past months. In April, it acquired the life sciences business of Canada's Skura Corporation for an undisclosed amount. This acquisition would help the firm expand its software suite for life sciences, product development capabilities in North America and global life science customer base, it said at the time.
In December 2015, it acquired health analytics platform SmartCare from Connecticut-based Vantage Point, Inc for $6-8 million.
VCCircle had first reported last year that Indegene was close to buying two US health-tech firms.
The company has around 1,400 employees and offices in Montreal, Los Angeles, Atlanta, Shanghai, Zurich and Bangalore.
It catered to the domestic market till 2004 and later decided to change its strategy to focus on the overseas market. A little later, Infosys co-founder NS Raghavan’s Nadathur Holdings invested in the firm, offering an exit to KITVEN Fund, which had invested in Indegene in 2002.
Like this report? Sign up for our daily newsletter to get our top reports.
